BioLine Rebounds as Trial Lifts Outlook: Israel Overnight

BioLineRX Ltd. is rebounding from a record low after the Israeli drugmaker’s leukemia treatment was approved for a second round of testing in the U.S., bolstering a company that hasn’t turned a profit since 2010.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.